Companies › Laboratoires Thea
5 active drug programs in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Ophthalmology, Immunology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sepofarsen (QR-110) CEP290 mRNA positive modulator | CEP290 | Phase 3 | Leber Congenital Amaurosis 10 | Nov 2027 |
| T1695 | – | Phase 2 | Moderate to Severe Vernal Keratoconjunctivitis | Jan 2027 |
| T10430 | – | Phase 2 | Myopia | Nov 2027 |
| Ultevursen USH2A exon 13 gene therapy | USH2A | Phase 2 | Retinitis Pigmentosa (RP) | Jul 2028 |
| T4090 Kinezodianone R hydrochloride | – | Phase 1 | Glaucoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05389267 | T4090 | Phase 1 | Glaucoma | Ophthalmology | Dec 2024 |
| NCT07169695 | T1695 | Phase 2 | Moderate to Severe Vernal Keratoconjunctivitis | Immunology | Jan 2027 |
| NCT06891443 | Sepofarsen (QR-110) | Phase 3 | Leber Congenital Amaurosis 10 | Ophthalmology | Nov 2027 |
| NCT07522242 | T10430 | Phase 2 | Myopia | Ophthalmology | Nov 2027 |
| NCT06627179 | Ultevursen | Phase 2 | Retinitis Pigmentosa (RP) | Ophthalmology | Jul 2028 |
Ocugen ProQR Therapeutics Huons Vantage Biosciences Sunhawk Vision Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.